Matthew Potenza is an Endocrinology/Metabolic physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 9 publications with 821 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2 Crosfield Ave Ste 204
Apt 10f
West Nyack, NY 109942221
Telephone
845-358-6266Registry record last updated 14 Oct 2009.
Industry payments
53 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Xeris Pharmaceuticals, Inc.Program year202522 payments
- BETA BIONICS, INC.Program year202513 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202514 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
48.4%GLP-1 receptor agonist15.3%Ozempic65%Mounjaro26%Trulicity8%Victoza 3-Pak1%Part D<11 patientsSGLT2 inhibitor9.9%Jardiance57%Farxiga27%Synjardy Xr16%Part D≥120 patients+ 8 more classes in this area
Musculoskeletal
22.6%RANK Ligand Inhibitor22.2%Denosumab100%Part B, office-administered≥20 patientsBisphosphonates0.4%Risedronate Sodium100%Part D≥12 patientsCardiovascular
14.4%Statin7.4%Atorvastatin Calcium58%Rosuvastatin Calcium38%Simvastatin4%Part D<11 patientsAngiotensin receptor blocker (ARB)3%Losartan Potassium61%Valsartan16%Irbesartan12%Losartan-Hydrochlorothiazide7%Olmesartan Medoxomil5%Part D<11 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Intravenous Ibandronate Acutely Reduces Bone Hyperresorption in Chronic Critical Illness
Journal of Intensive Care Medicine
2011 - Targeting the Incretin System in Type 2 Diabetes Mellitus
Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine
2009
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”